Earnings call transcript: iRhythm beats Q2 2025 forecasts with strong revenue growth

iRhythm Technologies Inc. (IRTC) reported a strong Q2 2025, significantly surpassing expectations with an adjusted net loss of $0.32 per share (vs. -$0.51 forecast) and revenue of $186.7 million, a 26.1% year-over-year increase. The company also improved its adjusted EBITDA margin by 500 basis points and raised its full-year 2025 revenue guidance to $720-$730 million, citing robust core business performance, successful innovative channel partnerships, and EHR integrations. While the stock saw minimal movement post-earnings, it maintains strong year-to-date gains, reflecting investor confidence in its growth trajectory and path to positive free cash flow by 2026, despite ongoing FDA remediation efforts.

Analysis

iRhythm Technologies (IRTC) delivered a robust Q2 2025, significantly outperforming market expectations and demonstrating accelerating operational momentum. The company reported revenue of $186.7 million, a 26.1% year-over-year increase, and a narrower-than-expected adjusted net loss of $0.32 per share, beating the forecast of a $0.51 loss. This performance was driven by strength in its core Zio Monitor and Zio AT product lines, supplemented by growing contributions from new innovative channel partnerships with entities like Signify Health and CenterWell. Critically, the company showcased significant operating leverage, with adjusted EBITDA margin improving by 500 basis points to 8.4%. Management's confidence is reflected in the raised full-year 2025 revenue guidance to $720-$730 million, an increase primarily attributed to sustained core business strength. While the stock's immediate reaction was muted, its 55.46% year-to-date return suggests the market has been pricing in this strong execution. Key forward-looking catalysts include the upcoming Q3 2025 submission for its next-generation Zio MCT product and the continued expansion of high-impact EHR integrations with platforms like Epic, which are reportedly increasing prescribing patterns by 20-40%. Despite the positive results, the company is still working to resolve a formal FDA warning letter, which remains a key risk factor, though management states all required responses have been submitted. The clear path towards achieving positive free cash flow in 2026, coupled with strong fundamental growth, presents a compelling narrative.

Key Decisions for Investors

• Investors should view the significant revenue beat and raised full-year guidance as strong validation of the company's core growth strategy and commercial execution.
• Monitor the adoption rate and revenue contribution from innovative channel partnerships and Epic EHR integrations, as these are key leading indicators for sustained outperformance beyond the core business.
• The primary risk remains the unresolved FDA warning letter; while progress is reported, the timing and outcome of a final inspection represent a key uncertainty that must be factored into risk assessments.
• The planned Q3 2025 regulatory filing for the next-generation Zio MCT product is a critical catalyst to watch, as a successful launch could significantly increase market share in a segment where iRhythm is currently underpenetrated.
• Given the stock's significant year-to-date run-up, investors may consider the balance between the strong operational momentum and the valuation, which appears to have priced in much of the positive news.